We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Codexis Announces Three-Year Extension of Collaboration Agreement with Merck
Product News

Codexis Announces Three-Year Extension of Collaboration Agreement with Merck

Codexis Announces Three-Year Extension of Collaboration Agreement with Merck
Product News

Codexis Announces Three-Year Extension of Collaboration Agreement with Merck


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Codexis Announces Three-Year Extension of Collaboration Agreement with Merck"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As the collaboration enters its sixth year, Merck will continue to use Codexis’ proprietary enzyme products to develop more cost- and resource-efficient manufacturing processes for its pipeline of therapeutic candidates.  The initial agreement was announced in April 2007 and today’s agreement provides an extension to 2015.

Merck has evaluated the use of Codexis enzymes extensively across programs in various stages of development. In addition, the companies have collaborated to develop enzymes for custom reactions, most notably for sitagliptin, the active pharmaceutical ingredient in Merck’s Januvia®.

“We are very pleased to continue this important relationship,” said Peter Strumph, Interim Chief Executive Officer.  “Our collaboration with Merck has led to a number of breakthroughs in pharmaceutical manufacturing that have been adopted by Merck in some of their leading pharmaceutical products. We look forward to continuing to develop additional cost-advantaged manufacturing processes with Merck.”

“Through this agreement we are very pleased to be extending our ongoing productive research collaboration with Codexis,” said Christopher Hill, Ph.D., Global Head of Chemistry Research at Merck.

Advertisement